Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double‐blind, randomized, placebo‐controlled trial

Anand, Amit; Gunn, Abigail D.; Barkay, Gavriel; Karne, Harish; Nürnberger, John I.; Mathew, Sanjay J.; Ghosh, Samiran

doi:10.1111/j.1399-5618.2011.00971.x

Cited by 59 publications

(49 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are insufficient data to make a recommendation regarding the use of aspirin (adjunctive) (level 3 negative),296 celecoxib (adjunctive) (level 3 negative),297 gabapentin (monotherapy) (level 3 negative),298 leviteracitam (adjunctive) (level 3 negative),299 lisdexamfetamine (adjunctive) (level 3 negative),300 memantine (adjunctive) (level 3),301 pioglitazone (adjunctive) (level 3),302, 303 riluzole (level 4 negative),304 and risperidone (adjunctive) (level 3) 305. Although adjunctive therapy with pregnenolone separated from placebo at week 6, the change in depressive symptoms was not significantly different from week 8 to week 12 between the two groups (level 2) 306…”

Section: Acute Management Of Bipolar Depressionmentioning

confidence: 99%

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder

et al. 2018

View full text Add to dashboard Cite

The Canadian Network for Mood and Anxiety Treatments (CANMAT) previously published treatment guidelines for bipolar disorder in 2005, along with international commentaries and subsequent updates in 2007, 2009, and 2013. The last two updates were published in collaboration with the International Society for Bipolar Disorders (ISBD). These 2018 CANMAT and ISBD Bipolar Treatment Guidelines represent the significant advances in the field since the last full edition was published in 2005, including updates to diagnosis and management as well as new research into pharmacological and psychological treatments. These advances have been translated into clear and easy to use recommendations for first, second, and third‐ line treatments, with consideration given to levels of evidence for efficacy, clinical support based on experience, and consensus ratings of safety, tolerability, and treatment‐emergent switch risk. New to these guidelines, hierarchical rankings were created for first and second‐ line treatments recommended for acute mania, acute depression, and maintenance treatment in bipolar I disorder. Created by considering the impact of each treatment across all phases of illness, this hierarchy will further assist clinicians in making evidence‐based treatment decisions. Lithium, quetiapine, divalproex, asenapine, aripiprazole, paliperidone, risperidone, and cariprazine alone or in combination are recommended as first‐line treatments for acute mania. First‐line options for bipolar I depression include quetiapine, lurasidone plus lithium or divalproex, lithium, lamotrigine, lurasidone, or adjunctive lamotrigine. While medications that have been shown to be effective for the acute phase should generally be continued for the maintenance phase in bipolar I disorder, there are some exceptions (such as with antidepressants); and available data suggest that lithium, quetiapine, divalproex, lamotrigine, asenapine, and aripiprazole monotherapy or combination treatments should be considered first‐line for those initiating or switching treatment during the maintenance phase. In addition to addressing issues in bipolar I disorder, these guidelines also provide an overview of, and recommendations for, clinical management of bipolar II disorder, as well as advice on specific populations, such as women at various stages of the reproductive cycle, children and adolescents, and older adults. There are also discussions on the impact of specific psychiatric and medical comorbidities such as substance use, anxiety, and metabolic disorders. Finally, an overview of issues related to safety and monitoring is provided. The CANMAT and ISBD groups hope that these guidelines become a valuable tool for practitioners across the globe.

show abstract

Section: Acute Management Of Bipolar Depressionmentioning

confidence: 99%

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Quality assessed with the Jadad scale ( Table 1; eTable 1) indicated that 4 studies Keck et al, 2009;Kelly, 2008b;Schrauwen and Ghaemi, 2006) had no quality (Jadad's scale=0), 4 (Gildengers et al, 2008;Iosifescu et al, 2009;Keck et al, 2009;Koukopoulos et al, 2012) had low quality (Jadad's scale=1), 1 (Iosifescu et al, 2009) had medium quality (Jadad's scale=2), and 5 (Ae et al, 2006;Anand et al, 2012;Ghaemi et al, 2009;Lee et al, 2014) were of high quality (Jadad's scale>3). All the studies with high quality were also RCTs, while among the studies with other designs, only 1 (Iosifescu et al, 2009) included a control group, reaching a medium quality.…”

Section: Methodological Quality Of Included Studiesmentioning

confidence: 99%

“…All studies focused on the short-or medium-term treatment and none reported results on relapse prevention. Nine studies were conducted in the USA (Ae et al, 2006;Anand et al, 2012;Burt et al, 1999;Ghaemi et al, 2009;Gildengers et al, 2008;Iosifescu et al, 2009;Keck et al, 2009;Kelly, 2008a;Schrauwen and Ghaemi, 2006), 2 in Asia Lee et al, 2014) and one in Europe (Koukopoulos et al, 2012). Five studies were RCTs, 2 naturalistic case series, 2 retrospective case series, 2 open label trials without a control group and 1 with a control group.…”

Section: Study and Patient Characteristicsmentioning

confidence: 99%

“…Three studies (Ghaemi et al, 2009;Iosifescu et al, 2009;Schrauwen and Ghaemi, 2006) explored the effect of galantamine (treated=21; controls: 20, 10 placebo and 10 healthy subjects), one was a RCT (Ghaemi et al, 2009). Four studies (Anand et al, 2012;Keck et al, 2009;Koukopoulos et al, 2012;Lee et al, 2014) investigated the use of memantine (treated=152; controls=88, all placebo) with 2 studies (Anand et al, 2012;Lee et al, 2014) with a RCT design. No study investigated rivastigmine effects in BD.…”

Section: Study and Patient Characteristicsmentioning

confidence: 99%

“…The 12 included studies (Ae et al, 2006;Anand et al, 2012;Burt et al, 1999;Chen et al, 2013;Ghaemi et al, 2009;Gildengers et al, 2008;Iosifescu et al, 2009;Keck et al, 2009;Koukopoulos et al, 2012;Lee et al, 2014;Schrauwen and Ghaemi, 2006) included a total of 434 participants (treated=275, controls=147) for an average follow-up period of 20 weeks. All studies focused on the short-or medium-term treatment and none reported results on relapse prevention.…”

Section: Study and Patient Characteristicsmentioning

confidence: 99%

See 2 more Smart Citations

Acetylcholinesterase inhibitors and memantine in bipolar disorder: A systematic review and best evidence synthesis of the efficacy and safety for multiple disease dimensions

Veronese

Solmi

Luchini

et al. 2016

Journal of Affective Disorders

View full text Add to dashboard Cite

show abstract

Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults

McCloud

Caddy

Jochim

et al. 2015

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Reliable conclusions from this review are severely limited by the small amount of data usable for analysis. The body of evidence about glutamate receptor modulators in bipolar disorder is even smaller than that which is available for unipolar depression. Overall, we found limited evidence in favour of a single intravenous dose of ketamine (as add-on therapy to mood stabilisers) over placebo in terms of response rate up to 24 hours; ketamine did not show any better efficacy in terms of remission in bipolar depression. Even though ketamine has the potential to have a rapid and transient antidepressant effect, the efficacy of a single intravenous dose may be limited. Ketamine's psychotomimetic effects could compromise study blinding; this is a particular issue for this review as no included study used an active comparator, and so we cannot rule out the potential bias introduced by inadequate blinding procedures.We did not find conclusive evidence on adverse events with ketamine. To draw more robust conclusions, further RCTs (with adequate blinding) are needed to explore different modes of administration of ketamine and to study different methods of sustaining antidepressant response, such as repeated administrations. There was not enough evidence to draw meaningful conclusions for the remaining two glutamate receptor modulators (memantine and cytidine). This review is limited not only by completeness of evidence, but also by the low to very low quality of the available evidence.

show abstract

Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double‐blind, randomized, placebo‐controlled trial

Cited by 59 publications

References 26 publications

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder

Acetylcholinesterase inhibitors and memantine in bipolar disorder: A systematic review and best evidence synthesis of the efficacy and safety for multiple disease dimensions

Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults

Contact Info

Product

Resources

About